Beximco Pharmaceuticals Limited (BXP.L) announced the launch of generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme and Ridgeback Biotherapeutics. Beximco Pharma's generic version of molnupiravir will be marketed as Emorivir. It will initially be launched in Bangladesh.
Beximco Pharma noted that molnupiravir is the world's first oral antiviral drug to treat COVID-19. Molnupiravir was approved by the UK's Medicines and Healthcare products Regulatory Agency on 4 November 2021.
Based on current infection rates in Bangladesh, Beximco Pharma does not expect a material impact on full-year revenues.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.